Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis

Company Overview

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $42.04 to $43.52
• 50-Day Range: $41.46 to $51.91
• 52-Week Range: $20.08 to $57.28
• Volume: 428,338 shs
• Average Volume: 703,683 shs
• Market Capitalization: $1.80 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $66.17
• Consensus Rating: Buy

Tarsus Pharmaceuticals Stock Analysis - MarketRank™

Tarsus Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 539th out of 930 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Tarsus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Tarsus Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($3.17) to ($1.44) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tarsus Pharmaceuticals is -11.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tarsus Pharmaceuticals is -11.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tarsus Pharmaceuticals has a P/B Ratio of 7.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.18% of the float of Tarsus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Tarsus Pharmaceuticals has recently decreased by 6.38%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tarsus Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Tarsus Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

22.18% of the float of Tarsus Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Tarsus Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Tarsus Pharmaceuticals has recently decreased by 6.38%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.04

News Sentiment

Tarsus Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Tarsus Pharmaceuticals this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for TARS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,581,173.00 in company stock.

Percentage Held by Insiders

Only 8.25% of the stock of Tarsus Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

TARS Stock Analysis - Frequently Asked Questions

How have TARS shares performed this year?

Tarsus Pharmaceuticals' stock was trading at $55.37 at the start of the year. Since then, TARS shares have decreased by 22.4% and is now trading at $42.94.
View the best growth stocks for 2025 here.

How were Tarsus Pharmaceuticals' earnings last quarter?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) posted its earnings results on Thursday, May, 1st. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative trailing twelve-month return on equity of 55.86%.
Read the conference call transcript.

When did Tarsus Pharmaceuticals IPO?

Tarsus Pharmaceuticals (TARS) raised $80 million in an initial public offering on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers.

Who are Tarsus Pharmaceuticals' major shareholders?

Tarsus Pharmaceuticals' top institutional investors include Paradigm Biocapital Advisors LP (6.21%), Jennison Associates LLC (6.50%), Vanguard Group Inc. (5.30%) and Frazier Life Sciences Management L.P. (3.33%). Insiders that own company stock include Bobak R Azamian, Seshadri Neervannan, Aziz Mottiwala, Bryan Wahl, Dianne C Whitfield, Leonard M Greenstein, Elizabeth Yeu Lin, Mark J Holdbrook, Andrew D Goldberg and Jose M Trevejo.
View institutional ownership trends.

How do I buy shares of Tarsus Pharmaceuticals?

Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Tarsus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 5/31/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TARS
• CIK: 1819790
• Web: www.tarsusrx.com
• Phone: 949-409-9820
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $66.17
• High Stock Price Target: $84.00
• Low Stock Price Target: $51.00
• Potential Upside/Downside: +54.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$135.89 million
• Net Margins: -103.64%
• Pretax Margin: -103.64%
• Return on Equity: -55.86%
• Return on Assets: -39.28%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 5.42
• Quick Ratio: 5.38

Sales & Book Value

• Annual Sales: $233.67 million
• Price / Sales: 7.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.95 per share
• Price / Book: 7.22

Miscellaneous

• Outstanding Shares: 42,014,000
• Free Float: 35,073,000
• Market Cap: $1.80 billion
• Optionable: Optionable
• Beta: 0.94